

CME INSTITUTE

collective mindfulness

#Tweertorial: Analyzing Two Schizophrenia Case Reports

May 2, 2023

[VIEW ON TWITTER](#)

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Faculty Affiliations

John Lauriello, MD

Professor and Chair of Psychiatry and Human Behavior
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York


Amber R Hoberg, PMHNP-BC

Psychiatric Nurse Practitioner
Morning Star Family Medicine
San Antonio, Texas

Financial Disclosure

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:



CME INSTITUTE

collective mindfulness

Ms. Hoberg is a consultant for Teva, Neurocrine. Has received speaker honoraria from Teva, Neurocrine, Intracellular Therapies, Avanir, Acadia, Axsome, and BioXcel. She has also received advisory board fees from Teva, Acadia, Intracellular Therapies, Sunovion and Neurocrine.

Dr. Lauriello is a consultant for Karuna Pharmaceuticals, Avanir Therapeutics, Teva and BioXcel .

Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva. He is a stockshare holder for Bristol-Myers Squibb, Eli Lilly, J & J, Merck and has stock options for Reviva. He has received speaker honoraria from AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, and Teva. He has received publishing/royalty income from Royalties/Publishing Income: Taylor & Francis, Wiley, International Journal of Clinical Practice, UpToDate , Springer Healthcare, Elsevier.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.

Tweetorial References

Tweet #10

Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. *Schizophr Res.* 2014;152(2-3):408-414.

Tweet #11

Kane JM, Schooler NR, Marcy P, et al. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. *J Clin Psychiatry.* 2019 Apr 23;80(3):18m12546. doi: 10.4088/JCP.18m12546.

Tweet #12


Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. *Am J Psychiatry.* 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503.

Tweet #14

Sheehan JJ, Reilly KR, Fu DJ, Alphas L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. *Innov Clin Neurosci.* 2012 Jul;9(7-8):17-23.

Tweet #15

Grover S, Sahoo S, Subodh BN, et al. Attitude and perceptions of patients towards long acting depot injections. *Asian J Psychiatr.* 2019;44:200-208.



CME INSTITUTE

collective mindfulness

Iyer S, Banks N, Roy M-A, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I—patient perspectives. *Can J Psychiatry*. 2013;58(5).

Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A. Opinions of French patients with schizophrenia regarding injectable medication. *Patient Prefer Adherence*. 2011 Mar 21;5:165-71. doi: 10.2147/PPA.S15337. PMID: 21573047; PMCID: PMC3090377.

Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. *Neuropsychiatr Dis Treat*. 2022;18:111-123.

Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. *CNS Spectr*. 2017;22(S1):14-28.

Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? *Advances in Psychiatric Treatment*. 2005; 11(3): 203-211.

Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. *Can J Psychiatry*. 2013;58(5 Suppl 1):s23-9.

Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. *CNS Drugs*. 2021;35(11):1189-1205.

Tweet #16

Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A. Opinions of French patients with schizophrenia regarding injectable medication. *Patient Prefer Adherence*. 2011 Mar 21;5:165-71. doi: 10.2147/PPA.S15337.

Tweet #19

Gardner, KN et al. Managing first-episode psychosis: Rationale and evidence for nonstandard first-line treatments for schizophrenia. *Current Psychiatry*. 2015 July;14(7):33, 38-45, e3

Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. *J Clin Psychiatry*. 1996;57 Suppl 11:68-71.

Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. *Br J Psychiatry Suppl*. 1998;172(33):53-9.

Tweet #20

Fernando P, Sommer IEC, Hasan A. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? *Curr Opin Psychiatry*. 2020;33(3):192-199.

Tweet #22

Schoretsanitis G, Baumann P, Conca A, et al. Therapeutic drug monitoring on long-acting injectable antipsychotic drugs. *Ther Drug Monit*. 2021;43(1):79-102.



CME INSTITUTE

collective mindfulness

GLOSSARY

AA Antipsychotic Agent

AE Adverse Event

APA American Psychiatric Association

CC Clinician's Choice

HCP Healthcare Professional

LAI Long-Acting Injectable

LAI AA Long-Acting Injectable Antipsychotic Agent

LAIA Long-Acting Injectable Antipsychotic

OA Oral Antipsychotic

OA AA Orally-Administered Antipsychotic Agent

OA SGA Orally-Administered Second-Generation Antipsychotic

PK/PD Pharmacokinetics/Pharmacodynamics

SGA Second-Generation Antipsychotic

TD Tardive Dyskinesia

TRRIP Treatment Response and Resistance in Psychosis

© Physicians Postgraduate Press, Inc.